4220 articles
A novel 3D tactile label for drop bottles, designed to increase the accurate identification of medication and improve compliance in low vision patients, was correctly ‘read’ by 92% of test patients in
Left uncorrected, astigmatism can lead to reduced visual acuity, visual fatigue, poor overall vision quality and contact lens (CL) dropout, according to the Centre for Ocular Research & Education’s (C
Following a successful inaugural year, Myopia Profile has announced the return of Myopia Action Month in September 2024. The global event will deliver 30 days of tailored education and industr
Launched at O-Show 2024, Optique Line’s latest addition, Aikō Eyewear received a warm welcome from patrons, said Erika Siabatto, Optique Line’s marketing manager. The brand brings a blend of Nordic, Japanese and Australian contemporary designs, crafted with quality, playfulness and unique global aes
Attracting attention on Optimed’s stand from paediatric ophthalmologists and ophthalmic nurses was NeoLight’s Icon retinal imaging system, designed specifically to screen premature babies both in large hospital settings and in more remote areas.
Eye Health Aotearoa (EHA) will run a nationwide New Zealand Children’s Eye Health Campaign in September, finishing on World Sight Day on 10 October 2024.
This year’s Specsavers Clinical Conference (SCC) will be held from 14-15 September at the JW Marriott Gold Coast Resort & Spa and online. Bringing together optometry and ophthalmology professionals
A Chinese research team has developed a new ‘smart’ contact lens (CL) that can continuously monitor intraocular pressure (IOP), regardless of environmental temperature fluctuations. Led by Dengbao X
In an ocean of technical advances, a one-stop software shop, offering a fully customised, device-agnostic practice management system to ophthalmology clinics, was described as a technology breakthrough at RANZCO 2024. “GoodX brings a different software package to New Zealand, which no one else seems
US researchers have found that deleting a gene in mice reduced the subretinal fibrosis associated with nAMD, indicating a new therapeutic target to treat the nearly two-thirds of nAMD patients for whom anti-VEGF treatment is ineffective.
Preliminary results of a clinical trial of MyopiaX, a low-level laser device to treat progressive myopia in children, showed it was safe and tolerable and produced proof-of-concept data, reported its German developer Dopavision.
The authors of a University of Auckland study investigating the safety of UVC light to treat microbial keratitis said evidence of DNA damage was limited to the superficial epithelium. The study, led
